ArticleOncology letters2024

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Shigeo Shimose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.